HbA1c measurements allow for projection of renal outcomes

• Conditions: N08.3; Glomerular disorders in diabetes mellitus

• Registration Number: DRKS00031687
• Lead Sponsor: niversitätsklinikum Freiburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-04-17
• Study Completion: 2023-06-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 29653

Inclusion Criteria

at least one HbA1c measurement
- at least two serum-creatinine measurements
- follow-up of at least 12 months
- Subjects treated between January 1st, 1997 and September 30th, 2022

Exclusion Criteria

Inclusion criteria are not met

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint was defined as new-onset CKD (CKD stage = 3, starting from CKD stage 1 or 2 or absent CKD).

Secondary Outcome Measures

Name	Time	Method
Secondary endpoints were defined as<br> (S1) progression of CKD (S1, time to CKD stage = 4-5, starting from CKD stage 3) and <br>(S2) new-onset severe CKD (S2, time to CKD stage = 4-5 from CKD stage 1 or 2, respectively).